Teladoc Health, Inc. (TDOC)
USD 9.46
(-6.06%)
USD 9.46
(-6.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 153.99 Million USD | -98.57% |
| 2022 | -13.38 Billion USD | 94428.21% |
| 2021 | -84.67 Million USD | 95.8% |
| 2020 | -438.01 Million USD | -1078.03% |
| 2019 | -41.49 Million USD | 4.91% |
| 2018 | -35.25 Million USD | 29.56% |
| 2017 | -70.42 Million USD | 9.13% |
| 2016 | -62.84 Million USD | 6.85% |
| 2015 | -50.92 Million USD | -296.9% |
| 2014 | -12.83 Million USD | -150.83% |
| 2013 | -5.11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 49.66 Million USD | -2805.57% |
| 2024 Q1 | 23.42 Million USD | -66.99% |
| 2024 Q3 | -44.4 Million USD | 108.91% |
| 2023 Q1 | 24.51 Million USD | -99.36% |
| 2023 Q3 | 40.39 Million USD | 29.68% |
| 2023 Q4 | -257.57 Million USD | -737.71% |
| 2023 FY | - USD | -98.57% |
| 2023 Q2 | 31.14 Million USD | 27.07% |
| 2022 FY | - USD | 94428.21% |
| 2022 Q4 | 3.82 Billion USD | 61140.48% |
| 2022 Q1 | -1.27 Million USD | -106.44% |
| 2022 Q2 | -1.96 Million USD | -54.56% |
| 2022 Q3 | -6.27 Million USD | -219.13% |
| 2021 FY | - USD | 95.8% |
| 2021 Q4 | 19.75 Million USD | 1381.89% |
| 2021 Q3 | -1.54 Million USD | 87.39% |
| 2021 Q1 | -20.27 Million USD | 94.38% |
| 2021 Q2 | -12.22 Million USD | 39.72% |
| 2020 Q4 | -360.89 Million USD | -2040.1% |
| 2020 Q3 | 18.6 Million USD | 216.63% |
| 2020 FY | - USD | -1078.03% |
| 2020 Q1 | -6.11 Million USD | -89.8% |
| 2020 Q2 | 5.87 Million USD | 196.01% |
| 2019 Q1 | -10.31 Million USD | -50.63% |
| 2019 Q3 | -6.53 Million USD | 34.73% |
| 2019 Q2 | -10 Million USD | 2.96% |
| 2019 Q4 | -3.22 Million USD | 50.64% |
| 2019 FY | - USD | 4.91% |
| 2018 Q3 | -5.87 Million USD | 29.83% |
| 2018 Q1 | -9.27 Million USD | 36.51% |
| 2018 FY | - USD | 29.56% |
| 2018 Q4 | -6.84 Million USD | -16.55% |
| 2018 Q2 | -8.37 Million USD | 9.7% |
| 2017 Q4 | -14.6 Million USD | -121.31% |
| 2017 FY | - USD | 9.13% |
| 2017 Q3 | -6.59 Million USD | 32.07% |
| 2017 Q2 | -9.71 Million USD | 20.37% |
| 2017 Q1 | -12.19 Million USD | -14.69% |
| 2016 Q2 | -12.9 Million USD | 2.29% |
| 2016 Q1 | -13.2 Million USD | -3.18% |
| 2016 Q4 | -10.63 Million USD | 7.17% |
| 2016 FY | - USD | 6.85% |
| 2016 Q3 | -11.45 Million USD | 11.24% |
| 2015 Q1 | -11.69 Million USD | -110.82% |
| 2015 FY | - USD | -296.9% |
| 2015 Q4 | -12.8 Million USD | -15.27% |
| 2015 Q3 | -11.1 Million USD | 27.56% |
| 2015 Q2 | -15.32 Million USD | -31.12% |
| 2014 Q1 | -1.77 Million USD | 0.0% |
| 2014 Q3 | -3.2 Million USD | -39.19% |
| 2014 Q4 | -5.54 Million USD | -72.9% |
| 2014 Q2 | -2.3 Million USD | -29.88% |
| 2014 FY | - USD | -150.83% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Well Corporation | -225.99 Million USD | 168.143% |
| Doximity, Inc. | 195.46 Million USD | 21.216% |
| Evolent Health, Inc. | -24.78 Million USD | 721.331% |
| MultiPlan Corporation | 651.93 Million USD | 76.378% |
| Phreesia, Inc. | -102.94 Million USD | 249.592% |
| Veeva Systems Inc. | 429.33 Million USD | 64.131% |